Funding for this research was provided by:
The Danish Cancer Society and the AIDS Foundation (Not applicable)
The Aragon Foundation (Not applicable)
The Foundation of Aase and Ejnar Danielsens (Not applicable)
The Foundation of Anna and Preben Simonsen (Not applicable)
Received: 2 May 2019
Accepted: 13 August 2019
First Online: 22 August 2019
Ethics approval and consent to participate
: At entry, written and oral informed consent was obtained from all participants. The study and the DHCS were approved by the Danish Data Protection Agency (2012-41-0005, 2012-58-0004 and 2015–231-0126). Further, the study was approved by the Danish Regional Committee on Health Research Ethics (H-3-2010-119 and H-2-2014-102).
: Not Applicable.
: KT has received research funding from Abbott, a travel grant from Janssen-Cilag and honoraria from Janssen-Cilag, BMS and GlaxoSmithKline/Viiv. Since the paper in question was initiated, SL, has taken up a position in Novo Nordisk A/S working within the insulin franchise. For this paper SL is affiliating Clinical Research Centre, Copenhagen University Hospital, Hvidovre. MS has received an unrestricted grant from Gilead. TLK has received research funding and/or honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, GlaxoSmithKline/Viiv, Abbott, Gilead, and Janssen-Cilag. AML has received travel grant and/or honoraria from Bristol-Myers Squibb, Gilead and GlaxoSmithKline. JB attended meetings with various HPV device manufacturers. JB used to serve as a paid advisor to Roche and Genomica and has received honoraria from Hologic/Gen-probe, Roche, Qiagen, Genomica, and BD Diagnostics for lectures, and is the principal investigator on projects funded by BD Diagnostics, Genomica, and Qiagen. IJ, GP, FR, LNN, LN, MF, and NO discloses no competing interest.